New Insights on Fak and Fak Inhibitors

被引:15
|
作者
Brullo, Chiara [1 ]
Tasso, Bruno [1 ]
机构
[1] Univ Genoa, Dept Pharm, Viale Benedetto XV 3, I-16132 Genoa, Italy
关键词
Focal adhesion kinase; Fak inhibitors; metastasis; cancer therapy; clinical trials; PROTACS; FOCAL-ADHESION KINASE; NUCLEAR FAK; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ENDOTHELIAL FAK; CANCER; PYK2; PATHWAYS; ANTITUMOR;
D O I
10.2174/0929867327666201103162239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine ki-nase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years, different investigations have highlighted the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to the cardiac function or viral infection. Methods: An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships (SAR). Results: At the moment, only a few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak inhibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today in clinical trials and the recent chemical scaffolds (also included in patents) giving the most interesting results are investigated. In addition, PROTAC molecules are reported. Conclusion: All reported results evidenced that additional studies are necessary to design and synthesize new selective and more active compounds, although promising information has been obtained from associations between Fak inhibitors and other different anti-cancer drugs. In addition, the other important roles evidenced, both at the nuclear level and in non-cancerous cells, make this protein an increasingly important target in pharmaceutical chemistry. <comment>Superscript/Subscript Available</comment
引用
收藏
页码:3318 / 3338
页数:21
相关论文
共 50 条
  • [21] New insights into FAK signaling and localization based on detection of a FAT domain folding intermediate
    Dixon, RDS
    Chen, YW
    Feng, D
    Khare, SD
    Prutzman, KC
    Schaller, MD
    Campbell, SL
    Dokholyan, NV
    STRUCTURE, 2004, 12 (12) : 2161 - 2171
  • [22] Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential
    Li, Yingnan
    Zhang, Yuming
    Zhang, Jifa
    Zhan, Zixuan
    Mao, Wuyu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 279
  • [23] Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity
    Koide, Eriko
    Mohardt, Mikaela L.
    Doctor, Zainab M.
    Yang, Annan
    Hao, Mingfeng
    Donovan, Katherine A.
    Kuismi, Christina C.
    Nelson, Alissa J.
    Abell, Kathryn
    Aguiar, Mike
    Che, Jianwei
    Stokes, Matthew P.
    Zhang, Tinghu
    Aguirre, Andrew J.
    Fischer, Eric S.
    Gray, Nathanael S.
    Jiang, Baishan
    Nabet, Behnam
    CHEMBIOCHEM, 2023, 24 (19)
  • [24] Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
    Marlowe, Timothy A.
    Lenzo, Felicia L.
    Figel, Sheila A.
    Grapes, Abigail T.
    Cance, William G.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3028 - 3039
  • [25] Design, synthesis, and SAR of focal adhesion kinase (FAK) inhibitors
    Roberts, Walter Gregory
    Berliner, Martin
    Coleman, Kevin
    Emerson, Erling
    Griffor, Matt
    Hulford, Catherine
    Jani, Jitesh
    Kath, John
    LaGreca, Susan
    Lin, Jing
    Lorenzen, Marianne J.
    Marr, Eric
    Martinez-Alsina, Luis
    Patel, Nandini
    Richter, Daniel
    Roberts, Erika
    Autry, Christopher
    Ung, Ethan
    Felix, Vajdos
    Vetelino, Beth
    Wessel, Matthew
    Whalen, Pamela
    Xu, Huiping
    Yao, Lili
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [26] Roles and inhibitors of FAK in cancer: current advances and future directions
    Hu, Hui-Hui
    Wang, Sai-Qi
    Shang, Hai-Li
    Lv, Hui-Fang
    Chen, Bei-Bei
    Gao, She-Gan
    Chen, Xiao-Bing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] FAK inhibitors as promising anticancer targets: present and future directions
    Mustafa, Muhamad
    Abd El-Hafeez, Amer Ali
    Abdelhafeez, Dalia A.
    Abdelhamid, Dalia
    Mostafa, Yaser A.
    Ghosh, Pradipta
    Hayallah, Alaa M.
    Abuo-Rahma, Gamal El-Din
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (18) : 1559 - 1590
  • [28] Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
    Cao, Fang-Yuan
    Zhou, Xiao-Ping
    Su, Jing
    Yang, Xiao-Hong
    Mu, Feng-Hui
    Shen, Jia-Yi
    Sun, Wei
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2016, 16 (08) : 934 - 941
  • [29] Discovery of FAK Inhibitors Using Structure Based Drug Design
    Nam, Ky-Youb
    Jin, Dong-Hoon
    No, Kyoung Tai
    Ahn, Soon Kil
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2014, 35 (11) : 3156 - 3157
  • [30] A dominant-negative provides new insights into FAK regulation and function in early embryonic morphogenesis
    Petridou, Nicoletta I.
    Stylianou, Panayiota
    Skourides, Paris A.
    DEVELOPMENT, 2013, 140 (20): : 4266 - 4276